Trial Profile
Study of the Immune Response T Anti-tumoral CD4 for Patients Treated for a Metastatic Breast Cancer by Everolimus Within the Framework of Its Marketing Authorization
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 24 Apr 2024
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Advanced breast cancer
- Focus Pharmacodynamics
- Acronyms EVERIMMUN
- 28 Feb 2019 Planned End Date changed from 1 Dec 2020 to 1 May 2022.
- 28 Feb 2019 Planned primary completion date changed from 1 May 2020 to 1 May 2022.
- 16 Oct 2017 Planned End Date changed from 1 Dec 2018 to 1 Dec 2020.